---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009781"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:52:54.564756+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics accelerates EMPEROR enrollment, expects Phase 3 data in mid-2027, cash $391.7M

## Summary
- Enrollment of 150 patients in Phase 3 EMPEROR study expected to complete in Q2 2026, accelerated from prior timeline.
- Phase 3 data readout planned for mid-2027; rolling NDA submission to initiate in first half 2027.
- FDA multidisciplinary meeting held; no immediate program changes, but discussions ongoing for expedited pathways.
- Cash, equivalents and marketable securities $391.7M as of Dec 31, 2025; plus Biogen proceeds funds operations into 2028.
- Nearly 330 potential study candidates identified globally; ~60 in screening, ~60 randomized/dosed.

## SEC filing metadata
- accession: 0001193125-26-009781
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312526009781/0001193125-26-009781-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312526009781/d36198d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009781
- JSON: https://secwatch.observer/filing/0001193125-26-009781.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009781.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.